i
Reducing the burden of HPV-associated cancer and disease through vaccination in the US
-
February 19, 2013
Details:
-
Alternative Title:Looking forward - global and domestic HPV vaccination programs;Overview of HPV vaccines and impact monitoring;Overview of HPV vaccines and monitoring vaccine impact;Prevention of HPV-associated disease : global and domestic overview;Public health importance of human papillomavirus infection and disease;US HPV vaccination program, progress and challenges;What is needed to increase HPV vaccine coverage;
-
Personal Author:
-
Corporate Authors:Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication. ; Centers for Disease Control and Prevention (U.S.). Office of Surveillance, Epidemiology and Laboratory Services. Public Health Informatics & Technology Program Office. ; National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Cancer Prevention and Control. ; National Center for HIV, Viral Hepatitis, STD and TB Prevention (U.S.). Division of STD Prevention. ; National Center for Immunization and Respiratory Diseases (U.S.). Division of Immunization Services.
-
Description:This session of Grand Rounds explored the burden of human papillomavirus (HPV) -associated cancer and disease in the United States and prevention through HPV vaccination. HPV is the most common sexually transmitted infection in the United States. There are more than 40 HPV types, some of which cause cancers and others which cause genital warts. Each year, there are an estimated 26,000 HPV-attributable cancers in the United States. About 17,000 occur in women, most of which are cervical cancers, and about 9,000 occur in men, most of which are oropharyngeal cancers. CDC estimates that $8 billion are spent each year on direct medical costs for preventing and treating HPV-associated disease. Currently available HPV vaccines prevent infection from the HPV types that cause about 70% of cervical cancers and the majority of other HPV-attributable cancers. HPV vaccine has been recommended for routine vaccination of 11-12 year-old girls since 2006 and for 11-12 year-old boys since 2011. This session also provided more insight about the HPV vaccination program and how CDC, state and local health departments, and health care providers are working together to achieve high vaccination levels and reduce the substantial burden of HPV-associated disease.
-
Content Notes:Streaming video (1:01:39. : sd., col.).
Presented by: Mona Saraiya, MD, MPH, CAPT, U.S. Public Health Service, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC ["Public health importance of human papillomavirus infection and disease"]; Eileen F. Dunne, MD, MPH, CAPT, U.S. Public Health Service, Epidemiology and Statistics Branch, Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC ["Overview of HPV vaccines and monitoring vaccine impact"]; Shannon Stokley, MPH, Acting Associate Director of Science, Division of Immunization Services, National Center for Immunization and Respiratory Diseases, CDC ["US HPV vaccination program, progress and challenges" ]; Amy Middleman, MD, MSEd, MPH, Associate Professor and Director, Adolescent and Young Adult Immunization, Texas Children's Hospital Center for Vaccine Awareness and Research ["What is needed to increase HPV vaccine coverage?"]; Lauri E. Markowitz, MD, Team Lead, Epidemiology and Statistics Branch, Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC ["Looking forward - global and domestic HPV vaccination programs"]
Facilitated by: Tanja Popovic, MD, PhD, Scientific Director, Public Health Grand Rounds, John Iskander, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds, Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds
Recorded Tuesday, February 19, 2013.
Mode of access: World Wide Web as streaming video (766 MB, total time: 1:01:39); and as Acrobat .pdf files: (2.3 MB, 74 p.) containing PowerPoint slides for the speakers' talks.
Open-captioned.
-
Subjects:
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
Supporting Files
-
No Additional Files
More +